$PODD -Truist lowers Insulet target to $219 from $250 Buy - $PRCT -Leerink lowers PROCEPT BioRobotics target to $29 from $31 Downgrades to Market Perform from Outperform - $PSA -JPMorgan raises Public Storage target to $338 from $291 Neutral -

𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -18.4% S&P500 YTD: 8.6% TOTAL RETURNS (Jan 2022) Natan's portfolio: 82.1% *Benchmark: 41.6% S&P500: 65.1% MY POSITIONS: 21.5% | Transmedics $TMDX 15.5% | Robinhood $HOOD 14.5% | Pinduoduo $PDD 10.3% | Meta Platforms $META 9.4% | Procept BioRobotics $PRCT 7.1% | Alibaba $BABA 6.6% | Wizz Air $WIZZ 5.3% | Paypal $PYPL 4.0% | Monday $MNDY 3.2% | Regeneron $REGN 2.6% | Moderna $MRNA Follow me: @nataninvesting - - - - - - - - - - - - - - - - - - - * 𝘉𝘦𝘯𝘤𝘩𝘮𝘢𝘳𝘬 𝘪𝘴 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘦𝘥 𝘢𝘴 𝘢 𝘸𝘦𝘪𝘨𝘩𝘵𝘦𝘥 𝘢𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘰𝘭𝘭𝘰𝘸𝘪𝘯𝘨 𝘳𝘦𝘵𝘶𝘳𝘯𝘴: - 70% 𝘕𝘢𝘴𝘥𝘢𝘲 𝘊𝘰𝘮𝘱𝘰𝘴𝘪𝘵𝘦 𝘌𝘛𝘍 - 30% 𝘊𝘩𝘪𝘯𝘢 𝘐𝘯𝘵𝘦𝘳𝘯𝘦𝘵 𝘒𝘞𝘌𝘉 𝘌𝘛𝘍 ** 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

i think if you wanna invest you should invest into biorobotics chinese companies unironically

AwesomeCapital: Leerink downgrades Procept BioRobotics to Market P... awesomecapital.blogspot.com/…

US Stock Market | Major #Brokerage Analyst Calls | 11 June 2026 🔹 $PRCT (Procept BioRobotics): Leerink downgraded the surgical robotics company from Outperform to Market Perform and lowered its target price to $29 from $31. 🔹 $DAKT (Daktronics Inc.): Roth Capital initiated coverage with a Buy rating and an initial price target of $26. 🔹 $VOYG (Voyager Technologies Inc.): BTIG initiated coverage with a Buy rating and established a $55 price target. 🔹 $SNSE (Sensei Biotherapeutics Inc.): BTIG initiated coverage with a Buy rating and a target price of $55. 🔹 $TMO (Thermo Fisher Scientific Inc.): Piper Sandler initiated coverage with a Neutral rating and a $510 price target. 🔹 $DHR (Danaher Corporation): Piper Sandler initiated coverage with a Neutral rating and set a $200 price target. 🔹 $CALY (Topgolf Callaway Brands): Goldman Sachs assumed coverage with a Neutral rating and a $17 price target. 🔹 Key Takeaway: Analyst activity was largely positive, with notable upgrades for Intel, Black Hills, Henry Schein, and CME Group, while MarketAxess and Procept BioRobotics faced rating downgrades. #USStockMarket #AnalystCalls #BrokerageUpdates #WallStreet #Intel #CMEGroup #HenrySchein #BlackHills #MarketAxess #ThermoFisher #Danaher #Investing #StockMarket #MarketUpdate #June112026

ROBOTIC STOCKS to watch 🤖 Medical Robots Intuitive Surgical $ISRG Procept BioRobotics $PRCT Medtronic $MDT Industrial Robots Teradyne $TER Honeywell $HON Tesla $TSLA Logistics Robots Amazon $AMZ Symbotic $SYM Serve Robotics $SERV Defense Robots AeroVironment $AVAV Kratos $KTOS RTX Corp. $RTX Robot Automation Zebra Technologies $ZBRA Rockwell Automation $ROK UiPath $PATH Robot Software Nvidia $NVDA Qualcomm $QCOM Palladyne $PDYN Save the list for later 🔖

PRCT Procept BioRobotics. Aquablation robotic system for prostate (BPH) treatment. Less invasive than traditional TURP, better outcomes. Procedures are accelerating fast. TAM is huge. Could be the da Vinci of urology.

A German defence startup called SWARM Biotactics fitted live Madagascar hissing cockroaches with tiny electronic backpacks carrying cameras and sensors. Low-voltage signals nudge the insect's nerves so an operator can steer it in real time. They crawl through rubble, tunnels, and tight spaces where drones and robots simply cannot go. Built for search, rescue, and defence missions. The German military is already among their first customers. NATO forces are using them. Nobody designed a better machine for these spaces. So they used the one nature already built. #SWARMBiotactics #Biorobotics #NATO

$POCI Precision Optics Corporation Inc I have listened to the last 4 earnings calls and am about to increase my position in this company. They are the U.S. domestic vertically integrated manufacturer of micro-optics. The market for their products is growing like dough, and their record-breaking quarters are additional evidence of that. POCI is a relatively small company offering custom tiny optics for two major industries that are POCI's revenue pillars: - medical - defense/aerospace Recently, they added Satellite Communications (i.e., LEO) as a third pillar, a future growth area they're now actively pursuing. Demand for these micro-optics is growing because of new developing trends. Medical industry: - shift toward single-use scopes for a variety of procedures to eliminate cross-contamination (I remember how in the Soviet Union grocery stores used shared cups to serve milkshakes; after the USSR collapsed, single-use cups were slowly but permanently adopted); - growing demand for minimally invasive surgeries, which require advanced micro-optics. Defense industry: - experiencing a renaissance in technological inspection devices, for example, borescopes to inspect jet engines, etc. - the CEO also stated that there are opportunities in niches ranging "from autonomous vehicles to directed energy weapons." Satellite communication: - shifting from Radio Frequency to optical inter-satellite links (laser comms) for the growing LEO satellite business. Clients: POCI doesn't disclose customer names, but publicly available information strongly suggests its AR fighter-pilot training program supports Red 6, the US Air Force's exclusive AR combat training vendor. Their single-use cystoscope partner is widely speculated to be PROCEPT BioRobotics, based on the technical match. Intuitive Surgical is a confirmed historical customer (POCI's website states they were an early partner on the da Vinci robotic surgery system). What is special about POCI? - They are based in the US; - Vertically integrated; - They design custom optics from scratch for every client, develop prototypes, and handle mass production which helps them stand out against giants like Corning, ZEISS, etc.; - They provide agility and decades of expertise to satisfy demanding customer needs; - Their optics can operate in extreme conditions; - They recently expanded their facilities to increase production and raised capital for growth. POCI has two major revenue streams: - a design and prototyping arm - and manufacturing. For each client, they run a dedicated "engineering program" first, and then a "production program." The largest production program is currently Medical but in terms of a single client, it is Aerospace/Defense. POCI considers Space as the third strategic market focus . Now they have: - up to 6 engineering programs (production could start in FY2027) - 3 active production programs: Aerospace/Defense (top-tier aerospace customer) $3.6M in Q3 FY2026 Single-use cystoscope (surgical robotics customer) $2.2M in Q3 FY2026 Single-use ophthalmic program ramping, ~$2-3M expected in CY2026 Because the optics are custom, initial yields start low and improve over time. For example, the ophthalmic line yields went from ~60% in November to over 90% within a few months. That impacts revenue and margin. Financials: Record-breaking revenue, quarter after quarter: Q4 FY2025 - $6.2m Q1 FY2026 - $6.7m Q2 FY2026 - $7.4m Q3 FY2026 - $8.7m Aerospace backlog only is $9m Almost break-even and about to reach profitability. Margin is about 23%, with a trajectory to improve to 30% by the end of FY2026. Debt is under $2m They raised FY2026 revenue guidance to $31m, up from $25m The CEO stated that demand is not just growing it is accelerating. New facility provides capacity headroom. POCI can grow production without needing additional capex on top of what they've already committed. Market cap is $62.8m (June 5 2026). P/S: 2.03x on FY2026 guidance of $31m To conclude: There is a clear trend toward adopting micro-optics. POCI's clients are in trending niches like Defense, Robotics and potentially Space. These clients need more advanced technology for their medical devices, robots, military systems, and space hardware. POCI has the expertise and assets to create those advanced products custom and fast. It's a pick-and-shovel play with revenue growth of 50%–100% YoY, a 30% margin guidance, and a business that is about to become profitable. not financial advice / DYOR.

𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 😑 Natan YTD: -18.6% S&P500 YTD: 7.9% TOTAL RETURNS (Jan 2022) Natan's portfolio: 81.6% *Benchmark: 40.6% S&P500: 64.0% MY POSITIONS: 20.6% | Transmedics $TMDX 15.2% | Pinduoduo $PDD 13.8% | Robinhood $HOOD 10.8% | Meta Platforms $META 10.3% | Procept BioRobotics $PRCT 7.6% | Alibaba $BABA 6.2% | Wizz Air $WIZZ 5.3% | Paypal $PYPL 4.4% | Monday $MNDY 3.3% | Regeneron $REGN 2.5% | Moderna $MRNA Follow me: @nataninvesting - - - - - - - - - - - - - - - - - - - * 𝘉𝘦𝘯𝘤𝘩𝘮𝘢𝘳𝘬 𝘪𝘴 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘦𝘥 𝘢𝘴 𝘢 𝘸𝘦𝘪𝘨𝘩𝘵𝘦𝘥 𝘢𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘰𝘭𝘭𝘰𝘸𝘪𝘯𝘨 𝘳𝘦𝘵𝘶𝘳𝘯𝘴: - 70% 𝘕𝘢𝘴𝘥𝘢𝘲 𝘊𝘰𝘮𝘱𝘰𝘴𝘪𝘵𝘦 𝘌𝘛𝘍 - 30% 𝘊𝘩𝘪𝘯𝘢 𝘐𝘯𝘵𝘦𝘳𝘯𝘦𝘵 𝘒𝘞𝘌𝘉 𝘌𝘛𝘍 ** 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

If the entire playing squads of all 48 World Cup teams had double above-knee amputations and time-traveling biorobotics experts from a number of years equivalent to each country's FIFA ranking performed reconstructive surgery on the players who do think would win the tournament?

𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -17.2% S&P500 YTD: 10.7% TOTAL RETURNS (Jan 2022) Natan's portfolio: 84.8% *Benchmark: 46.4% S&P500: 68.3% MY POSITIONS: 19.5% | Transmedics $TMDX 15.5% | Robinhood $HOOD 14.8% | Pinduoduo $PDD 11.3% | Meta Platforms $META 9.5% | Procept BioRobotics $PRCT 7.7% | Alibaba $BABA 6.3% | Wizz Air $WIZZ 5.7% | Paypal $PYPL 4.2% | Monday $MNDY 3.1% | Regeneron $REGN 2.4% | Moderna $MRNA Follow me: @nataninvesting - - - - - - - - - - - - - - - - - - - * 𝘉𝘦𝘯𝘤𝘩𝘮𝘢𝘳𝘬 𝘪𝘴 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘦𝘥 𝘢𝘴 𝘢 𝘸𝘦𝘪𝘨𝘩𝘵𝘦𝘥 𝘢𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘰𝘭𝘭𝘰𝘸𝘪𝘯𝘨 𝘳𝘦𝘵𝘶𝘳𝘯𝘴: - 70% 𝘕𝘢𝘴𝘥𝘢𝘲 𝘊𝘰𝘮𝘱𝘰𝘴𝘪𝘵𝘦 𝘌𝘛𝘍 - 30% 𝘊𝘩𝘪𝘯𝘢 𝘐𝘯𝘵𝘦𝘳𝘯𝘦𝘵 𝘒𝘞𝘌𝘉 𝘌𝘛𝘍 ** 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

$PRCT pretty undervalued at these levels. Procept BioRobotics is positioned around Aquablation therapy, a robot-assisted, image-guided waterjet treatment for benign prostatic hyperplasia (BPH). Unlike heat-based or implant therapies, Aquablation uses real-time imaging robotic precision to selectively remove prostate tissue while aiming to reduce risk of sexual side effects and preserve continence. Key drivers: • Still low penetration in a large, under-treated BPH surgery market • Growing adoption in hospital urology departments as systems gain procedural experience • Included as an established surgical option in major urology treatment pathways (alongside TURP and newer minimally invasive options) • Expansion depends on installed base of robotic systems and recurring procedure utilization Fundamentals are great. Looks like good spot to bid TA wise💰

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval | $PRCT globenewswire.com/news-relea…

PRCT PROCEPT BioRobotics. ~$1.5B market cap. Only AI-powered robotic system for Aquablation therapy. Minimally invasive prostate treatment with better outcomes than traditional surgery. Q1 2026 revenue: $83M, up 20% YoY. 2026 guidance: $390M to $410M 27% to 33% growth.

𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -17.9% S&P500 YTD: 9.2% TOTAL RETURNS (Jan 2022) Natan's portfolio: 83.2% *Benchmark: 43.5% S&P500: 66.0% MY POSITIONS: 19.4% | Transmedics $TMDX 16.7% | Pinduoduo $PDD 12.2% | Robinhood $HOOD 11.0% | Meta Platforms $META 9.8% | Procept BioRobotics $PRCT 8.1% | Alibaba $BABA 7.3% | Paypal $PYPL 5.9% | Wizz Air $WIZZ 4.0% | Monday $MNDY 3.2% | Regeneron $REGN 2.4% | Moderna $MRNA Follow me: @nataninvesting - - - - - - - - - - - - - - - - - - - * 𝘉𝘦𝘯𝘤𝘩𝘮𝘢𝘳𝘬 𝘪𝘴 𝘤𝘢𝘭𝘤𝘶𝘭𝘢𝘵𝘦𝘥 𝘢𝘴 𝘢 𝘸𝘦𝘪𝘨𝘩𝘵𝘦𝘥 𝘢𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘰𝘭𝘭𝘰𝘸𝘪𝘯𝘨 𝘳𝘦𝘵𝘶𝘳𝘯𝘴: - 70% 𝘕𝘢𝘴𝘥𝘢𝘲 𝘊𝘰𝘮𝘱𝘰𝘴𝘪𝘵𝘦 𝘌𝘛𝘍 - 30% 𝘊𝘩𝘪𝘯𝘢 𝘐𝘯𝘵𝘦𝘳𝘯𝘦𝘵 𝘒𝘞𝘌𝘉 𝘌𝘛𝘍 ** 𝘛𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘐'𝘮 𝘯𝘰𝘵 𝘢 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘴𝘰𝘳 and all the 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘤𝘰𝘯𝘵𝘢𝘪𝘯𝘦𝘥 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘱𝘰𝘴𝘵 𝘪𝘴 𝘯𝘰𝘵 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

PROCEPT BIOROBOTICS $PRCT Buena evolución de ingresos gracias a sus avances en mejorar los problemas de próstata